Preliminary Q1 2017: revenue +8%, PBT +1% and NPAT pre-MI +15% vs Q1 2016, mostly thanks to tax benefits from the new Betalactam factory. These results are in line with DHG’s full-year guidance including revenue +15% and PBT +6%, and our expectation. Shareholders approved the FOL lift initiative. DHG will form an internal committee that will work with law firms and other advisors to find out how to position the company best for an FOL lift.